Interleukin-17A Contributed to the Damage of Blood-CNS Barriers During Streptococcus suis Meningitis

Lei Xu1,2, Xi Lu1,2, Peng Xiao1,2

  • 1State Key Laboratory of Agricultural Microbiology, Hubei Hongshan Laboratory, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, 430070, Hubei, China.

Molecular Neurobiology
|January 19, 2022
PubMed

Insights

Interleukin-17A (IL-17A) facilitates Streptococcus suis meningitis by downregulating tight junction proteins, increasing blood-CNS barrier permeability. This finding offers potential therapeutic targets for S. suis infections.

Area of Science:

  • Neuroscience
  • Immunology
  • Infectious Diseases

Background:

  • Streptococcus suis (S. suis) is a zoonotic pathogen causing severe meningitis in humans.
  • Interleukin-17A (IL-17A) is implicated in bacterial infections and blood-brain barrier integrity.
  • The specific role of IL-17A in S. suis meningitis requires further investigation.

Purpose of the Study:

  • To elucidate the role of IL-17A in the pathogenesis of meningitis caused by S. suis.
  • To investigate the effect of IL-17A on blood-central nervous system (CNS) barrier integrity during S. suis infection.

Main Methods:

  • Comparative analysis of S. suis infection in wild-type and IL-17A-deficient mice.
  • Assessment of mortality, organ damage, meningitis development, and clinical signs.
  • Evaluation of blood-CNS barrier permeability and tight junction (TJ) protein expression.

Main Results:

  • Meningitic S. suis infection led to acute death, multi-organ damage, and meningitis with neurological signs.
  • IL-17A deficiency did not significantly alter acute inflammatory responses or mortality but reduced meningitis and neurological signs.
  • IL-17A was found to inhibit the transcription and expression of TJ proteins, increasing blood-CNS barrier permeability.

Conclusions:

  • IL-17A plays a critical role in the development of S. suis meningitis by compromising the blood-CNS barrier.
  • Downregulation of TJ proteins by IL-17A facilitates bacterial invasion into the CNS.
  • Targeting IL-17A may offer a novel strategy for preventing and treating S. suis meningitis.